ArticleThe American journal of pathology2005
Deletion of Bid impedes cell proliferation and hepatic carcinogenesis.
Article in The American journal of pathology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 51 citations in OpenAlex.
- Network analysis of the effects of long non-coding RNAs in artemisinin treatment of atherosclerosis in APOEArchives of medical science : AMS · 2024Article
- Prognostic Value of Necroptosis-Related Genes Signature in Oral Squamous Cell Carcinoma.Cancers · 2023Article
- Promotion of diet-induced obesity and metabolic syndromes by BID is associated with gut microbiota.Hepatology communications · 2022Article
- The HMGB1-RAGE axis modulates the growth of autophagy-deficient hepatic tumors.Cell death & disease · 2020Article
- Cancer's Achilles' Heel: Apoptosis and Necroptosis to the Rescue.International journal of molecular sciences · 2016Review
- The Paradox of p53: What, How, and Why?Cold Spring Harbor perspectives in medicine · 2016Review
- Caspase-2 deficiency accelerates chemically induced liver cancer in mice.Cell death and differentiation · 2016Article
- A fate worse than death: apoptosis as an oncogenic process.Nature reviews. Cancer · 2016Review
- FAK Kinase Activity Is Required for the Progression of c-MET/β-Catenin-Driven Hepataocellular Carcinoma.Gene expression · 2016Article
- Gene Expression Analysis Indicates Divergent Mechanisms in DEN-Induced Carcinogenesis in Wild Type and Bid-Deficient Livers.PloS one · 2016Article
- Hepatocyte-specific Bid depletion reduces tumor development by suppressing inflammation-related compensatory proliferation.Cell death and differentiation · 2015Article
- FAK is required for c-Met/β-catenin-driven hepatocarcinogenesis.Hepatology (Baltimore, Md.) · 2015Article
- Rejuvenating Bi(d)ology.Oncogene · 2013Review
- Bid-ding for mercy: twisted killer in action.Cell death and differentiation · 2013Article
- Bid-overexpression regulates proliferation and phosphorylation of Akt and MAPKs in response to etoposide-induced DNA damage in hepatocellular carcinoma cells.OncoTargets and therapy · 2012Article
- PUMA-mediated apoptosis drives chemical hepatocarcinogenesis in mice.Hepatology (Baltimore, Md.) · 2011Article
- Bid is a positive regulator for donor-derived lymphoid cell regeneration in γ-irradiated recipients.Experimental hematology · 2011Article
- Deficiency of Bid protein reduces sepsis-induced apoptosis and inflammation, while improving septic survival.Shock (Augusta, Ga.) · 2010Article
- Bid agonist regulates murine hepatocyte proliferation by controlling endoplasmic reticulum calcium homeostasis.Hepatology (Baltimore, Md.) · 2010Article
- The strength of the Fas ligand signal determines whether hepatocytes act as type 1 or type 2 cells in murine livers.Hepatology (Baltimore, Md.) · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Mechanisms that control the proliferation capability of the initiated cells during hepatocarcinogenesis are still largely unclear. We investigated the role of a pro-death Bcl-2 family protein, Bid, in liver tumor development using a neonatal diethylnitrosamine model. Diethylnitrosamine was administrated to 15-day-old wild-type and bid-null mice. The development of microfoci at the early stage and of gross tumors at the later stage was compared between the two groups of mice. Both microfoci and gross tumor development were significantly retarded in the bid-null mice, despite reduced cell death as measured by TUNEL staining. Further studies indicated that there were significantly less proliferating cells in diethylnitrosamine-treated bid-null livers. The regulation of cell proliferation by Bid was confirmed in two other systems not involving carcinogenesis. Hepatocyte proliferation following partial hepatectomy and T lymphocyte proliferation following anti-CD3 stimulation were both retarded in bid-null mice. Thus, these studies revealed a previously undisclosed function of Bid in regulating cell proliferation, which can be important to tumor development. Furthermore, the role of Bid in promoting hepatocarcinogenesis is in contrast to its reported role in suppressing myeloid leukemia and thus suggests an organ- and/or etiology-specific role of the Bcl-2 family proteins in regulating oncogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.